Gilead Sciences saw two straight days of 5% gains after announcing a successful phase 2 trial for its combo next-gen interferon free pill for curing hepatitis C. It looks as if the company's combination treatment of sofosbuvir and ledipasvir, is on track to be the new standard of care after posting a 95% cure rate. 

In the following video, health-care analyst David Williamson discusses what this means for investors in the big biotech and its two closest competitors.

David Williamson has no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.

The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.